128 related articles for article (PubMed ID: 38719979)
1. Metabolomic screening of radioiodine refractory thyroid cancer patients and the underlying chemical mechanism of iodine resistance.
Zheng W; Tang X; Dong J; Feng J; Chen M; Zhu X
Sci Rep; 2024 May; 14(1):10546. PubMed ID: 38719979
[TBL] [Abstract][Full Text] [Related]
2. Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Shobab L; Gomes-Lima C; Zeymo A; Feldman R; Jonklaas J; Wartofsky L; Burman KD
Thyroid; 2019 Sep; 29(9):1262-1268. PubMed ID: 31319763
[No Abstract] [Full Text] [Related]
3. Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance.
Shen H; Zhu R; Liu Y; Hong Y; Ge J; Xuan J; Niu W; Yu X; Qin JJ; Li Q
Drug Resist Updat; 2024 Jan; 72():101013. PubMed ID: 38041877
[TBL] [Abstract][Full Text] [Related]
4. Clinical association of CXCR4 in primary tumor of papillary thyroid cancer and response to iodine-131 treatment.
Sirakriengkrai K; Tepmongkol S; Keelawat S; Techavijit U
Nucl Med Commun; 2021 Apr; 42(4):396-401. PubMed ID: 33306632
[TBL] [Abstract][Full Text] [Related]
5. Metabolomics reveals the implication of acetoacetate and ketogenic diet therapy in radioiodine-refractory differentiated thyroid carcinoma.
Wang J; Xu Q; Xuan Z; Mao Y; Tang X; Yang K; Song F; Zhu X
Oncologist; 2024 May; ():. PubMed ID: 38760956
[TBL] [Abstract][Full Text] [Related]
6. Enhancing Radioiodine Incorporation in
Tchekmedyian V; Dunn L; Sherman E; Baxi SS; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Knauf JA; Pfister DG; Fagin JA; Ho AL
Thyroid; 2022 Mar; 32(3):273-282. PubMed ID: 35045748
[No Abstract] [Full Text] [Related]
7. Clinicopathological features of differentiated thyroid carcinoma as predictors of the effects of radioactive iodine therapy.
Liu W; Jiang B; Xue J; Liu R; Wei Y; Li P
Ann Diagn Pathol; 2024 Apr; 69():152243. PubMed ID: 38128440
[TBL] [Abstract][Full Text] [Related]
8. Markedly elevated serum preoperative thyroglobulin predicts radioiodine-refractory thyroid cancer.
Cheng X; Xu S; Zhu Y; Wu J; Bao J; Yu H; Zhang L
Eur J Clin Invest; 2022 Apr; 52(4):e13721. PubMed ID: 34855206
[TBL] [Abstract][Full Text] [Related]
9. A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer.
Meng C; Song J; Long W; Mu Z; Sun Y; Liang J; Lin Y
Front Endocrinol (Lausanne); 2023; 14():1109439. PubMed ID: 36843580
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta-analysis.
Yu J; Liu Z; Su Y; Peng X; Xie Y
Clin Endocrinol (Oxf); 2024 Apr; 100(4):379-388. PubMed ID: 38351437
[TBL] [Abstract][Full Text] [Related]
11. Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features.
Lorusso L; Minaldi E; Esposito G; Piaggi P; Bottici V; Brogioni S; Giani C; Valerio L; Molinaro E; Elisei R; Agate L
J Endocrinol Invest; 2023 Oct; 46(10):2165-2173. PubMed ID: 37084131
[TBL] [Abstract][Full Text] [Related]
12. TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts absent or lower
Meng Z; Matsuse M; Saenko V; Yamashita S; Ren P; Zheng X; Jia Q; Tan J; Li N; Zheng W; Zhao L; Mitsutake N
IUBMB Life; 2019 Jul; 71(7):1030-1040. PubMed ID: 31026111
[TBL] [Abstract][Full Text] [Related]
13. TESC promotes differentiated thyroid cancer development by activating ERK and weakening NIS and radioiodine uptake.
Guo Y; Cai Y; Song F; Zhu L; Hu Y; Liu Y; Ma W; Ge J; Zeng Q; Ding L; Li L; Zheng G; Ge M
Endocrine; 2023 Sep; 81(3):503-512. PubMed ID: 37020077
[TBL] [Abstract][Full Text] [Related]
14. Radioactive Iodine-Refractory Pulmonary Metastases of Papillary Thyroid Cancer in Children, Adolescents, and Young Adults.
Tian T; Huang S; Dai H; Qi M; Liu B; Huang R
J Clin Endocrinol Metab; 2023 Jan; 108(2):306-314. PubMed ID: 36226635
[TBL] [Abstract][Full Text] [Related]
15.
Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
[No Abstract] [Full Text] [Related]
16. [Association of extranodal extension and lymph node ratio with radioactive iodine-refractory papillary thyroid cancer].
Luo ZY; Qin JW; Fang JG; Zheng C; Gong WB; Hei H
Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(48):3856-3861. PubMed ID: 36540923
[No Abstract] [Full Text] [Related]
17. Effect of thyroid-stimulating hormone in 68Ga-DOTATATE PET/CT of radioiodine-refractory thyroid carcinoma: a pilot study.
Almeida LS; Araújo MC; Zantut-Wittmann DE; Assumpção LV; Souza TF; Silva CM; Argenton JL; Santos AO; Mengatti J; Ramos CD; Etchebehere EC
Nucl Med Commun; 2018 May; 39(5):441-450. PubMed ID: 29543624
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis and targeted therapies for radioiodine refractory thyroid cancer.
Yu Q; Zhang X; Li L; Zhang C; Huang J; Huang W
Asia Pac J Clin Oncol; 2023 Jun; 19(3):279-289. PubMed ID: 35950297
[TBL] [Abstract][Full Text] [Related]
19. Ultrasound characteristics of cervical lesions in patients with radioiodine refractory differentiated thyroid cancer: A strobe-compliant article.
Gao L; Lin Y; Jiang Y; Li H; Gao Q; Xi X; Wang Y; Yang X; Lai X; Zhu S; Zhang X; Zhao R; Zhang B
Medicine (Baltimore); 2019 Nov; 98(45):e17876. PubMed ID: 31702656
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis and signaling pathways related to iodine-refractory differentiated thyroid cancer.
Zhao S; Zhao Y; Zhao Y; Wang G
Front Endocrinol (Lausanne); 2023; 14():1320044. PubMed ID: 38313845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
